上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2014年
21期
39-41
,共3页
谢传华%曾小娟%王志强%郭守俊
謝傳華%曾小娟%王誌彊%郭守俊
사전화%증소연%왕지강%곽수준
新辅助化疗%胃癌%预后%术后转移
新輔助化療%胃癌%預後%術後轉移
신보조화료%위암%예후%술후전이
neoadjuvant chemotherapy%gastric cancer%prognosis%postoperative metastasis
目的:探讨新辅助化疗对胃癌患者预后和术后转移的影响。方法:将2008年1月至2010年1月期间于我院确诊为胃癌的患者100例按治疗方法分为观察组和对照组,每组患者50例。对照组采取常规治疗且均未接受新辅助化疗,观察组在对照组的基础上进行至少2周的新辅助化疗,治疗后患者均随访5年。比较两组的疗效、预后和术后转移情况。结果:观察组治疗有效率为76%,高于对照组的58%(P<0.05)。观察组术后发生肝转移、骨转移、淋巴结转移等术后转移发生率较对照组降低,观察组无瘤生存期和总生存期则均较对照组延长(P<0.05)。结论:新辅助化疗治疗胃癌疗效良好,可有效改善患者的预后并减少术后转移的发生,值得临床推广使用。
目的:探討新輔助化療對胃癌患者預後和術後轉移的影響。方法:將2008年1月至2010年1月期間于我院確診為胃癌的患者100例按治療方法分為觀察組和對照組,每組患者50例。對照組採取常規治療且均未接受新輔助化療,觀察組在對照組的基礎上進行至少2週的新輔助化療,治療後患者均隨訪5年。比較兩組的療效、預後和術後轉移情況。結果:觀察組治療有效率為76%,高于對照組的58%(P<0.05)。觀察組術後髮生肝轉移、骨轉移、淋巴結轉移等術後轉移髮生率較對照組降低,觀察組無瘤生存期和總生存期則均較對照組延長(P<0.05)。結論:新輔助化療治療胃癌療效良好,可有效改善患者的預後併減少術後轉移的髮生,值得臨床推廣使用。
목적:탐토신보조화료대위암환자예후화술후전이적영향。방법:장2008년1월지2010년1월기간우아원학진위위암적환자100례안치료방법분위관찰조화대조조,매조환자50례。대조조채취상규치료차균미접수신보조화료,관찰조재대조조적기출상진행지소2주적신보조화료,치료후환자균수방5년。비교량조적료효、예후화술후전이정황。결과:관찰조치료유효솔위76%,고우대조조적58%(P<0.05)。관찰조술후발생간전이、골전이、림파결전이등술후전이발생솔교대조조강저,관찰조무류생존기화총생존기칙균교대조조연장(P<0.05)。결론:신보조화료치료위암료효량호,가유효개선환자적예후병감소술후전이적발생,치득림상추엄사용。
Objective: To explore the effect of neoadjuvant chemotherapy (NAC) on prognosis and postoperative metastasis in patients with gastric cancer. Methods:One hundred gastric cancer patients diagnosed and treated in our hospital from January, 2009 to January, 2010 were divided into an observation group and a control group with 50 cases each according to the method for treatment. The control group was treated with conventional treatment without neoadjuvant chemotherapy while the observation group was treated with neoadjuvant chemotherapy for at least two weeks in the basis of the control group. Patients were followed up for 5 years after treatment. The efifcacy, prognosis, and postoperative metastasis in two groups were compared. Results:The treatment efifciency was 76%in the observation group, which is higher than the 58%in the control group (P<0.05). The incidence of liver metastases, bone metastases, lymph node metastasis and other postoperative metastasis was lower in the observation group than in the control group. The tumor-free survival period and overall survival period were longer in the observation group than in the control group (P<0.05). Conclusion:Neoadjuvant chemotherapy for the treatment of gastric cancer has good efifcacy and can effectively improve the prognosis of patients and reduce the occurrence of postoperative metastasis, which is worthy of clinical use.